About a third of people with major depression do not get better with the standard treatments. They try one antidepressant, then another, then a third. They go to therapy for years. They do everything that gets recommended — the exercise, the meditation, the books, the cognitive behavioral worksheets — and they remain depressed. Sometimes the depression lifts a little, then settles back down. Sometimes it never lifts at all. They start to wonder, in private, whether something is wrong with them in a way that can’t be reached.
This is the population the term “treatment-resistant depression” was coined for. It’s a clinical phrase, but it carries a personal one underneath: people who have done the work, taken the medicine, shown up for their own healing for years, and have not been met by their own treatment. If that’s the country you’ve been living in, this article is for you.
What treatment-resistant depression actually is
The clinical definition is simple. A person has treatment-resistant depression (TRD) when they’ve tried at least two adequate trials of standard antidepressants from different classes — usually meaning two or more SSRIs, SNRIs, or related medications, taken for the right amount of time at the right dose — and have not achieved remission.
By that definition, somewhere between thirty and forty percent of all depressed people qualify. That’s not a small footnote. That’s the better part of half of everyone in the diagnosis.
What it means experientially is harder to define and more important to name. People with TRD describe something that goes beyond sadness. There’s a flatness, a sense of being separated from the parts of life that used to feel like they mattered. There’s a loop that the mind keeps returning to no matter how many times you try to redirect it. There’s exhaustion that sleep doesn’t touch. There’s sometimes a private despair about the depression itself — not just the original pain, but the pain of having tried everything and remained where you started.
Most people with TRD have not failed at treatment. Treatment has failed them. That distinction matters.
Why standard treatments stop reaching certain people
The mainstream antidepressant family — SSRIs, SNRIs, tricyclics, MAOIs — works on the serotonin or norepinephrine systems. The theory is that depression involves a dysregulation of these neurotransmitters and that adjusting them upward will lift mood. For somewhere between half and two-thirds of people, this theory is roughly right. The medications help. Many people live full lives on them.
For the other third, something else is going on. The serotonin model doesn’t describe their depression accurately, and adjusting their serotonin doesn’t reliably move it. Newer research suggests that for many people in this group, the depression has more to do with the glutamate system, with chronic stress responses, with synaptic loss in the prefrontal cortex, and with rigid neural patterns that simply don’t respond to neurotransmitter adjustment. They have a different version of the same diagnosis, and it requires a different approach.
Talk therapy faces an analogous limit. Cognitive behavioral therapy and its relatives work by helping a person identify and reshape the patterns of thought and behavior that maintain depression. For many people this is genuinely useful. For others — particularly those whose depression has roots in early trauma, in pre-verbal experiences, in body-held grief, or in patterns so deeply set that the conscious mind cannot reach them — the cognitive frame can’t do all of the work. You can know exactly why you’re depressed and remain depressed. The knowing isn’t enough.
Most people with treatment-resistant depression have not failed at treatment. Treatment has failed them.
What ketamine does that other treatments don’t
The reason ketamine has reshaped the treatment landscape for depression is that it works on a different system, on a different timescale, with a different mechanism than anything else psychiatry has used.
Standard antidepressants take four to eight weeks to begin working, when they work. Ketamine begins lifting depression within hours of a single session.1 The Yale lab whose 2000 trial established this called the speed “the most surprising finding in psychiatry in fifty years.”2
The mechanism is also different. Ketamine acts on the glutamate system rather than the serotonin system. It triggers a cascade that increases brain-derived neurotrophic factor and produces synaptogenesis — the literal regrowth of neural connections that chronic depression has eroded. People with treatment-resistant depression often have measurably reduced synaptic density in the prefrontal cortex. Ketamine reverses this physically, not metaphorically.
And the comparative effectiveness data is striking. The 2023 ELEKT-D trial in the New England Journal of Medicine compared ketamine head-to-head against electroconvulsive therapy — the most aggressive treatment in standard psychiatry — for treatment-resistant depression. Ketamine matched ECT for efficacy and outperformed it on side effects. It’s the largest trial of its kind, and the headline is simple: for the population that has not responded to standard treatments, ketamine works as well as the most powerful conventional intervention available, with significantly less cognitive cost.3
Why a ceremonial container changes the outcomes
Most of the major ketamine research has been done in clinical infusion settings — a chair, an IV drip, monitoring equipment, sometimes a magazine to look at. The results in those settings are good. They’re also, often, less durable than they could be.
What clinical infusion models tend to underweight is something the research community is now openly discussing: the “non-pharmacological factors” that surround the medicine experience. The setting. The preparation. The person’s state of mind going in. The presence of guides who can hold what arises. The integration support afterward. These are not extras. They’re the conditions that determine whether the neuroplasticity ketamine creates becomes lasting therapeutic change or just a few weeks of good days.
This is why ceremonial ketamine, held in the kind of container we hold at Within Center, often produces deeper outcomes than the same molecule given in a clinic. Not because we’re mystical about it. Because we’re paying attention to the variables that the research literature increasingly recognizes as decisive.
For someone with treatment-resistant depression, the combination matters especially. The depression has often been there long enough to have shaped self-perception, relationships, and the very sense of what is possible. A medicine that opens the brain’s capacity to revise these patterns is most useful when paired with a setting that offers something to revise them toward — a different felt experience of safety, of being held, of being able to put down what has been carried for years.
What the experience tends to look like
People with TRD who come to ceremonial ketamine often describe the first session in similar terms. Something quiets. The relentless internal voice that has narrated their depression for years — the one that catalogues failures, that anticipates rejection, that explains why nothing will help — goes briefly silent. In that silence, often for the first time in years, they have direct contact with their own being without the depression as a filter.
What people do with that contact varies. Some weep. Some feel a peace they had stopped believing was available. Some encounter grief that has been waiting to be felt. Some have visual or symbolic experiences they can’t fully describe. Some simply rest, and notice that rest is possible.
Almost everyone reports, in the days afterward, that something has shifted. Not always dramatically. The depression isn’t necessarily “gone” the next morning. But the relationship to it has loosened. There is a small distance between the person and the depression that wasn’t there before. From that distance, change becomes possible in ways it wasn’t before.
For people who have been depressed for a long time, that small distance is enormous. It’s the difference between being inside a story and being able to see the story from outside.
What it doesn’t do
Ceremonial ketamine is not a cure. We use the word advisedly. There are people whose depression remits substantially and stays remitted for years. There are people whose depression lifts and returns. There are people who do a series of six sessions and rebuild a life. There are people for whom the medicine offers some relief but not transformation.
What we can say honestly: for the population with treatment-resistant depression, ceremonial ketamine has the highest probability of meaningful change of any treatment we’re aware of. That doesn’t mean it works for everyone. It means it works often enough, deeply enough, and for long enough that it’s the most reasonable next step for someone who has tried the standard path and not been met by it.
It also pairs unusually well with what came before. A person who has done years of therapy is, for ceremonial ketamine, ideally prepared. The conscious work has built the self-knowledge. The medicine helps that self-knowledge become embodied. People sometimes describe it as “finally being able to do what therapy had been pointing me at all along.”
What we recommend, practically
For someone with treatment-resistant depression considering ceremonial ketamine, a few honest recommendations.
Don’t come for one session and expect everything. Most of the durable change we see for TRD happens through a series — typically three to six sessions over two to three months. The medicine compounds. The first session opens what the second works with.
Don’t stop your other treatments without medical guidance. Ketamine combines safely with most antidepressants under appropriate supervision. It does not require, and we do not recommend, stopping medication abruptly to begin this work.
Stay in therapy. The combination of ceremonial work and good talk therapy is the strongest version of this. The therapy holds the integration; the medicine provides the openings.
Take the integration period seriously. Whatever happens during ceremony matters less than what you do with it in the weeks afterward. Build in space, journaling, conversation, sleep, movement. The plasticity window is short and decisive.
Be honest about safety. If you’ve had active suicidality, this is information your guides need to know. Ceremonial ketamine has been studied specifically in suicidal ideation and shown rapid effect, but it’s held differently in those cases — with more clinical support, more frequent check-ins, often closer integration with a psychiatrist. We can support this; we just need to know.
The deeper hope
The reason this medicine matters, and the reason we do this work, is that there is a population of people who have been told, sometimes implicitly, that nothing will help them. They’ve done the rounds. They’ve tried the things. They’ve resigned themselves, half or fully, to the depression as a permanent feature of their life.
It’s often not permanent. It’s often a pattern that the right kind of intervention can move. The current generation of research on ketamine and on psychedelic medicines is, more than anything else, the slow correction of a long pessimism about what depression actually is and what can be done about it. We’ve seen people whose lives had been organized around managing a depression they no longer have. We’ve seen people who had stopped expecting to feel joy notice, three weeks after a ceremony, that they had laughed, real and unguarded, for the first time in years.
None of this is promised. All of it is possible. If you’ve been carrying a depression that hasn’t answered to what you’ve tried, we’d be honored to talk with you about whether this work might be the next thing.